(MedPage Today) — First-line treatment with a recently approved targeted agent demonstrated durable efficacy in advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), results of the phase I Beamion LUNG-1 trial showed.
In 74 previously…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
